Active	Status	Sponsor type	Region	Phase	Filter
13 Active 7 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RIGALLEAU, Vincent
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia	Recruiting	3	300	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
Bouillet, Laurence
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Recruiting	2/3	463	Europe, US, RoW	Elenestinib, BLU-263, Placebo	Blueprint Medicines Corporation	Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis	06/28	06/28
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks	Recruiting	N/A	300	Europe, RoW	rhC1INH or pdC1INH, Ruconest	Pharming Technologies B.V.	Hereditary Angioedema	01/25	01/25
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)	Completed	N/A	1761	Europe, RoW		Shire, Takeda Development Center Americas, Inc.	Hereditary Angioedema (HAE)	05/24	05/24